Co-Authors
This is a "connection" page, showing publications co-authored by ANTHONY LUCCI and MEDIGET TESHOME.
Connection Strength
2.263
-
Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities. Ann Surg Oncol. 2024 Oct; 31(11):7326-7334.
Score: 0.242
-
Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Ann Surg Oncol. 2023 Oct; 30(10):6232-6240.
Score: 0.226
-
Lymphedema in Inflammatory Breast Cancer Patients Following Trimodal Treatment. Ann Surg Oncol. 2022 Oct; 29(10):6370-6378.
Score: 0.211
-
Contemporary surgical management of inflammatory breast cancer: a narrative review. Chin Clin Oncol. 2021 Dec; 10(6):57.
Score: 0.202
-
Inflammatory Breast Cancer at the Extremes of Age. Ann Surg Oncol. 2021 Oct; 28(10):5626-5634.
Score: 0.197
-
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021 Oct; 28(10):5477-5485.
Score: 0.196
-
Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Dec; 28(13):8610-8621.
Score: 0.196
-
The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol. 2021 Aug; 28(8):4265-4274.
Score: 0.190
-
Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? Ann Surg Oncol. 2020 Nov; 27(12):4603-4612.
Score: 0.184
-
Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open. 2024 Jun 03; 7(6):e2418486.
Score: 0.060
-
Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. Ann Surg Oncol. 2023 Nov; 30(12):7015-7025.
Score: 0.056
-
Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol. 2022 Oct; 29(10):6381-6392.
Score: 0.053
-
Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. J Surg Oncol. 2021 Dec; 124(7):989-994.
Score: 0.049
-
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2019 Oct; 26(10):3071-3079.
Score: 0.043
-
Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Pract Radiat Oncol. 2019 Nov; 9(6):402-409.
Score: 0.042
-
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951.
Score: 0.039
-
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer. 2018; 9(8):1437-1447.
Score: 0.039
-
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017 07 01; 152(7):665-670.
Score: 0.037